1 / 33

Eye Banking : biovigilance

Eye Banking : biovigilance. diego.ponzin@fbov.it The Veneto Eye Bank Foundation, Venice. Workshop on Quality Systems in Ocular Tissue Banking , TAIEX 50564 . Zagreb , Croatia, 30-31 January 2013. Biovigilance.

noam
Download Presentation

Eye Banking : biovigilance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Eye Banking: biovigilance diego.ponzin@fbov.itThe Veneto Eye Bank Foundation, Venice • Workshop on Quality Systems in Ocular Tissue Banking, TAIEX 50564. • Zagreb, Croatia, 30-31 January 2013

  2. Biovigilance • A set of surveillance procedures covering the entire transplantation chain (from the donation to the follow-up of recipients), intended to: • collect and assess information on unexpected or undesirable effects, and errors, resulting from the therapeutic use of blood products, organs, tissues, and cellular therapies; • prevent the occurrence or recurrence of such incidents; • improve clinical outcomes. • A permanent assessment of the risk / benefit ratio

  3. Biovigilance • The best opportunity to learn!

  4. The best opportunity to listen! • We have one mouth and two ears: in our dealing with others is enough to respect the ratio (…listentwiceasmuchasyouspeak)Epictetusquotes (Greek, Stoicphilosopher, born AD 55 The perfect murder is one that isn’t actually discovered Rabl Walter. European Hospital 2013;21(6)12:1-2

  5. The best opportunity to investigate The perfect murder is one that isn’t actually discovered Rabl Walter. European Hospital 2013;21(6)12:1-2

  6. Transparency Curvature

  7. LK: replacing only the diseased layers of the cornea • Safer surgery, faster visual recovery, better and more predictable visual outcome • DSAEK: refractive-neutral procedure, most common EK Tan DTH, Dart JKG, Holland EJ, Kinoshita S. Cornealtransplantation. Lancet 2012;379:1749-61

  8. EK: the eye bank work station Microkeratome Artificial anterior chamber

  9. Indicators (structure, process, outcome, efficiency, efficacy) • Positive: outcomes expected and pursued benefit • Negative: outcomes unexpected and unwanted risk • Tissue-related(adverse event, reaction) • SeriousAdverseEvent: somethingwrongduring the processcould cause harm to a patient • SeriousAdverseReaction: somethingwrong in a donor or in a patientcouldhavebeencaused by the tissues/cells • Non-tissue related(complication, failure) Directive 2004/23/EC: standards of quality and safety… Directive 2006/17/EC: technical requirements… Directive 2006/86/EC: traceability requirements, notification of serious adverse reactions and events…

  10. Tissue-related, negative indicators in corneal transplantation Any communicable or other disease transmissible by, and attributable to, transplantation of donor eye tissue, including: • Infections: systemic diseases, endophthalmitis (six months) keratitis (six weeks) • Biologic dysfunctions: immediate donor endothelial failure, donor corneal dystrophy, donor refractive surgery Eye Bank Association of America, Medical Standards, 2012

  11. Immediate donor endothelialfailure • Presence of a diffusely edematous penetrating corneal graft on the first postoperative day • Failure of the cloudy graft to clear at any time postoperatively • Lack of an identifiable cause of corneal graft failure • FBOV risk: 0.2% PK: biologic dysfunctions Wilhelmus KR. ArchOphtalmol1995;113:1497-502 • Donor corneal dystrophy • FBOV risk: <0.1%

  12. Endothelial rejection Cystoid macular edema LK: biologic dysfunctions, complications Graft dislocation Graft failure

  13. Risk of local transmission of bacteria, fungi, viruses • Pathology: keratitis, endophthalmitis, uveitis • Risk: <0.1% (bacteria, fungi), occasional (virus) • Prevention: donor screening, asepsis conditions, microbiological screening of tissues Herpetic keratouveitis after PK FBOV risk: • 0.05% (bacteria, fungi) • 0.005% (virus)

  14. Positive indicators for the evaluation ofclinical outcomes of corneal transplantation • Graft survival • Visual acuity (BCVA) • Anthalgiceffect • Reconstruction • Health related quality of life (SF-36, SF-12) • Visual function (VF14) • Surgeon’s satisfaction • Patient’s expectation and satisfaction • Delbosc et al, J FrOphthalmol, 2003. Fasolo A et al. Cornea 2006. Williams KA et al Eye, 1995. Vail A et al Ophthalmol, 1996. Bourne WM Ophthalmol, 1998. ClaessonM et al BJO, 2002. KA Williams et al Ophthalmol 1991. Uiters E et al Cornea2001; Fasolo A et al. J Ophthalmol2012.

  15. Biovigilance • The Agreement • The Procedures • The Reasons • Triennial agreement for the provision of services and tissues for ocular surgery

  16. The procedures • SOP - Standard Operating Procedures • Forms

  17. Cornea/Lenticule Request Form

  18. Non-SurgicalTissuesRequest/ UtilizationForms

  19. Cornea/Lenticule Evaluation Form

  20. Cornea/Lenticule Utilization Form

  21. Monitoring of adverse events / reactions

  22. Questionnaire of satisfaction

  23. The statistical report

  24. Reporting: the reasons • 200 surgeons involved

  25. Reporting: the reasons

  26. Donor-to-host transmission of Acanthamoeba from an asymptomatic cornea donor • Active monitoring • Cooperation with surgeons • Transparency • Rare events more likely to occur in high-volumes TE • Multidisciplinary approach • Dec 2009: thanksgiving letter sent to the eye bank by patient A (!)

  27. Results (2012) • Rate of reporting by FBOV cooperating surgeons: • Short term: 98% (within three months post op) • Long term: 44% (SAE /SAR monitoring), 37% (satisfaction) • Current risk: • Systemic diseases: theoretical • Endophthalmitis, keratitis: <0.1% (bacteria, fungi), <0.005% (virus) • Biologic dysfunctions: <0.2% • Current benefit: • Fasolo A et al. The CORTES study: corneal transplant indications and graft survival in an Italian cohort of patients. Cornea 2006; 25:507-15. • Fasolo A et al. Risk factors for graft failure after penetrating keratoplasty: 5 year follow-up from the Corneal Transplant Epidemiological Study. Cornea2011,30:1328–35. • FasoloA et al. Health status and patient satisfaction after corneal graft: results from the Corneal Transplant Epidemiological Study. J Ophthalmol2012; Vol2012, Art. ID 230641.

  28. Results Overall Kaplan–Meier probability of 5-year survival: 83.0% • Fasolo A et al. The CORTES study: corneal transplant indications and graft survival in an Italian cohort of patients. Cornea 2006; 25:507-15. • Fasolo A et al. Risk factors for graft failure after penetrating keratoplasty: 5 year follow-up from the Corneal Transplant Epidemiological Study. Cornea 2011,30:1328–35.

  29. Results • FasoloA et al. Health status and patient satisfaction after corneal graft: results from the Corneal Transplant Epidemiological Study. J Ophthalmol 2012; Vol 2012, Article ID 230641.

  30. A take-home message Leape LL. Reporting of adverseevents. NEJM 2002;347(20):1633-8

  31. Conclusions • Tissue Establishment, Surgeon, Competent Authority, Transplant Coordinators: an alliance to realize and improvement of patient’s care • Fundamental role of reporting is to enhance patient safety by learning from failures of the healthcare system • Individuals who report incidents must not be punished or suffer other ill-effects from reporting • Reporting: • reliable if based on positive arguments (clinicians involved) • only of value if it leads to a constructive response • must be personally, professionally, institutionally rewarding • Ponzin D et al. Eye banking at the Fondazione Banca degli Occhi del Veneto: present and perspectives. Organs and Tissues 2003; (2)111-9 • Ferrari S et al. Advances in corneal surgery and cell therapy: challenges and perspectives for the eye banks. Expert Review of Ophthalmology 2009; 4(3):317-29

More Related